The financials
ANI Pharmaceuticals, Inc. by the numbers
ANI Pharmaceuticals, Inc. (ANIP) reported revenue of $237M in Q1 2026 (quarter ended March 31, 2026), up 20% from the same quarter a year earlier. That came with a gross margin of 61% and net income of $29M (12% of revenue). For the full year FY2025, revenue was $883M (+44% year on year) and net income $78M. Its largest product in 2026-Q1 was Total Sales Of Rare Disease Pharmaceutical Products at $94M, 41% of the disclosed total, just ahead of Sales Of Cortrophin Gel at 32%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $237M | $197M | +20% |
| Gross profit | $144M | $124M | +16% |
| Operating income | $39M | $26M | +48% |
| Net income | $29M | $16M | +88% |
| Diluted EPS | $1.28 | $0.69 | +86% |
| Product | Revenue | Share |
|---|---|---|
| Total Sales Of Rare Disease Pharmaceutical Products | $94M | 41% |
| Sales Of Cortrophin Gel | $75M | 32% |
| Sales Of Established Brand Royalties And Other | $22M | 9.3% |
| Sales Of ILUVIEN And YUTIQ | $19M | 8.3% |
| Sales Of Established Brands | $12M | 5.3% |
| Unapproved Products | $6.3M | 2.7% |
| Sales Of Generic Other | $3.8M | 1.6% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $232.7M (-9.8%)
Sales Of Cortrophin Gel grew +42% year on yearSales Of Established Brands -51% year on year
Segment Latestquarter on quarteryear on year
- Total Sales Of Rare Disease Pharmaceutical Products$94.4M$94.4MQoQ -20%year on year +37%-20%+37%
- Sales Of Cortrophin Gel$75.1M$75.1MQoQ -26%year on year +42%-26%+42%
- Sales Of Established Brand Royalties And Other$21.5M$21.5MQoQ -year on year ---
- Sales Of ILUVIEN And YUTIQ$19.3M$19.3MQoQ +16%year on year +20%+16%+20%
- Sales Of Established Brands$12.3M$12.3MQoQ +15%year on year -51%+15%-51%
- Unapproved Products$6.3M$6.3MQoQ +5.0%year on year +15%+5.0%+15%
- Sales Of Generic Other$3.8M$3.8MQoQ -year on year -12%--12%
- Sales Of Royalties And Other Pharmaceutical Services--QoQ -year on year ---
Drug Manufacturers - Specialty & Generic
Ranks #10 of 28 by Smart Score